drugset / Trial / NCT07259161
Modified Conditioning Regimen for CML-BP
NaSingle-groupOpen-labelTreatment
Summary
Study on the Efficacy and Safety of a Reduced-Toxicity Conditioning Regimen Containing Thiotepa and Melphalan in Patients with Blast Phase Chronic Myeloid Leukemia
Timeline
- Start
- 2025-12-15
- Primary completion
- 2029-09-14
- Completion
- 2029-09-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |
| Background | Melphalan | Small molecule | 60 mg/m2 | — |
| Background | Thiotepa | Other / unclassified | 5 mg/kg | — |